Latest News

Présentation des données intermédiaires de l’étude ouverte OPTIC de Phase 2 d’Iclusig® (ponatinib) sur la LMC en phase chronique lors des réunions virtuelles de l’ASCO et de l’EHA

WILMINGTON, Del.–(BUSINESS WIRE)–Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings

Source link

Related posts

Anglican Women Novelists From Charlotte Brontë to P.D. James


Global Nutraceuticals Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Archer Daniels Midland Co. | Technavio


Could Brain Scans Spy Kids' Mood, Attention Problems?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World